The endorsement means the EMA will offer Carthera support and advice as it moves towards a regulatory filing for its ...

Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce ...

Following positive opinion, Carthera is one of the first companies to benefit from brand-new status – intended to support early access pathways for innovative devices targeting rare diseasesParis, ...

Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...